"Bristol-Myers CEO Unveils Acquisition Strategy for Company's Future"

Bristol-Myers Squibb CEO Chris Boerner discussed the company's recent acquisitions, emphasizing a transformative phase and the infusion of innovation. The pharmaceutical giant plans to acquire RayzeBio, Mirati Therapeutics, and Karuna Therapeutics, with a focus on advancing cancer drugs and neuropsychiatric medications. Boerner highlighted the potential of Karuna's new medication, KarXT, in treating schizophrenia and psychosis in Alzheimer's patients, citing its efficacy and reduced side effects.